수퍼삐셩

글로벌 시장 흐름의 변화 속에서 팩트와 인사이트를 찾는, 투자와 여행을 즐기는 직장인 미생, 인플루언서 팬하기

[Elevar Therapeutics @ElevarTx]

Breaking news! The FDA has approved our treatment for patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring a FGFR2 fusion or other rearrangement.

Read our #ElevarPressRelease: https://t.co/QcydA8eQso

#ElevarTx #ElevarTherapeutics #ElevatingOutcomes #news

[Elevar Therapeutics @ElevarTx]

We are pleased to announce that an abstract focusing on our investigational, highly selective FGFR2 inhibitor, lirafugratinib, will be presented at the 2026 ASCO Annual Meeting.

As we advance our mission to bring life-changing medicines to patients with limited options, this abstract highlights our commitment to addressing the unmet needs of patients.

Abstract #: TPS4251

Study: A Phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with FGFR2 fusion or rearrangement.

Focus: The ELE-4008-202, phase 2, open-label, single-arm study (NCT07359820) is designed to further evaluate the efficacy and safety of lirafugratinib 70 mg in patients with FGFR2 f/r, previously treated, unresectable, locally advanced or metastatic, non-CCA solid tumors who have not received prior FGFR inhibitor therapy (Richard Kim, MD, Moffit Cancer Center).

#ElevarTx #ElevarTherapeutics #Lirafugratinib #FGFR2 #ASCO26

[수퍼삐셩 @superbisheng]

@Jindo_1307979 178

[수퍼삐셩 @superbisheng]

@elonmuskTN 39

[rigetti @rigetti]

🚀Today we celebrate the launch of our 84Q Ankaa™-3 quantum computer, featuring an extensive hardware redesign, and 2Q gate fidelity milestones -- halving error rates to achieve a median 99.0% iSWAP gate fidelity and 99.5% median fidelity fSim gates. https://t.co/pbx0mOvMlW

[수퍼삐셩 @superbisheng]

@elonmuskADO answer is 44

[수퍼삐셩 @superbisheng]

[주식/HLB] 이제 Phase-2의 시작, 주가를 예단할 시기가 아니다. https://t.co/KDq62ON6Gn

[NKGen Biotech @NKGenBiotech]

NKGen CEO, Dr. Paul Song, spoke with DDW and explained the importance of developing therapies for patients with advanced Alzheimer's disease for which no approved disease-modifying therapies exist. Read here: https://t.co/yaJOBeTy3T $NKGN

[수퍼삐셩 @superbisheng]

#Vimeo에서 “Elevar - Impact of Liver Function on Survival Outcomes During Treatment With Camrelizumab + Rivoceranib vs Sorafenib in Patients” 시청하기 https://t.co/vlbNAMNAo4

[Immunomic Therapeutics @immunomix]

With heavy hearts, we share the news of Bill Hearl's passing on Feb. 5, 2024. As the visionary Founder and former CEO of Immunomic Therapeutics, Inc., Dr. Hearl leaves behind a legacy that will be cherished by many. He will be deeply missed.

[수퍼삐셩 @superbisheng]

일라이릴리처럼 가자 #HLB #elevartherapeutics

[수퍼삐셩 @superbisheng]

2024년 투자계획
[투자계획] 2024년 주식, 펀드 투자전략 수립, 투입금액 목표 5,400만원 설정
https://t.co/ephVANhl62

[NKGen Biotech @NKGenBiotech]

NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

https://t.co/t5i4VCwZfa

[NKGen Biotech @NKGenBiotech]

We are pleased to announce the nomination of two independent Board members for the post-business combination company. Please see press release below for more information.
https://t.co/5E11DUaQxE

[Elevar Therapeutics @ElevarTx]

We are proud to share @TheLancet published results from the pivotal phase 3 CARES 310 clinical trial for our investigational treatment of unresectable hepatocellular carcinoma (uHCC). At Elevar, we are committed to elevating outcomes for patients who have limited or inadequate therapeutic options. Read more: https://t.co/JJpteKgaEm

[TREASURE 글로벌 유니언 💎 @TREASUREunion]

#TREASURE was announced as one of the line-ups for TMEA (Tencent Music Entertainment Awards) 2023 "MUSIC FOR 4FUN" to be held on July 8th at Macau!

Another music festival stage for TREASURE to perform and show their amazing performance! ☺️

🔗https://t.co/mNDXWulzge

#トレジャ��� #트레저 @treasuremembers

[수퍼삐셩 @superbisheng]

#aacr2023 #elevar
[주식/에이치엘비] AACR2023���서 보여준 리보세라닙의 효능과 가치, 다른 사람들은 모��는 게 낫다. https://t.co/0PQQsrJIOz

[수퍼삐셩 @superbisheng]

#nkgenbiotech #grafaquisition
[주식/엔케이맥스] 엔케이젠바이오텍 뉴욕증권거래소 상장 확정 https://t.co/5MaABubSMY

[NKGen Biotech @NKGenBiotech]

Dr. Evren Alici joins NKGen as Scientific Advisor. Dr. Alici is Principal Researcher and Head of the Cell and Gene Therapy Group (CGTG) at the Karolinska Institutet Department of Medicine in Stockholm, Sweden. His expertise will provide invaluable support to our SNK programs.

[수퍼삐셩 @superbisheng]

[실현손익] 에스엠 전량매도, 에이치엘비, 엔케이맥스 추가 투자 진행 완료 (feat. 이오플로우, 셀트리온제약, 인팩, 에코프로에이치엔) https://t.co/DDbWGt5zkZ